Evommune shareholders elect directors, ratify auditor

Evommune, Inc. held its 2026 Annual Meeting of Stockholders on June 2, 2026, with a quorum present.

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Evommune, Inc. held its 2026 Annual Meeting of Stockholders on June 2, 2026, with a quorum present. Stockholders elected two directors to serve until the 2029 annual meeting or until their successors are elected and qualified.

Luis Peña was elected with 21,859,596 votes for and 1,949,148 votes withheld, while Eugene Bauer, M.D. received 23,637,920 votes for and 170,824 votes withheld. There were 885,750 broker non-votes for each nominee.

Stockholders also ratified the selection of BDO USA, P.C. as Evommune’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 24,664,299 votes for, 430 votes against, and 29,765 abstentions.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Key Figures

Votes for Luis Peña: 21,859,596 votes Votes withheld for Luis Peña: 1,949,148 votes Votes for Eugene Bauer, M.D.: 23,637,920 votes +5 more

8 metrics

Votes for Luis Peña 21,859,596 votes Election of director at 2026 annual meeting

Votes withheld for Luis Peña 1,949,148 votes Election of director at 2026 annual meeting

Votes for Eugene Bauer, M.D. 23,637,920 votes Election of director at 2026 annual meeting

Votes withheld for Eugene Bauer, M.D. 170,824 votes Election of director at 2026 annual meeting

Broker non-votes on director elections 885,750 votes For each director nominee at 2026 annual meeting

Votes for auditor ratification 24,664,299 votes Ratification of BDO USA, P.C. for 2026

Votes against auditor ratification 430 votes Ratification of BDO USA, P.C. for 2026

Abstentions on auditor ratification 29,765 votes Ratification of BDO USA, P.C. for 2026

Key Terms

Annual Meeting of Stockholders, Broker Non-Votes, independent registered public accounting firm, definitive proxy statement, +1 more

5 terms

Annual Meeting of Stockholders financial

"held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”), at which a quorum was present"

Broker Non-Votes financial

"The votes cast at the Annual Meeting were as follows ... Broker Non-Votes"

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

independent registered public accounting firm financial

"ratify the selection of BDO USA, P.C. as the Company’s independent registered public accounting firm"

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

definitive proxy statement regulatory

"each of which is described in more detail in the Company’s definitive proxy statement"

A Definitive Proxy Statement is a detailed document that a company sends to its shareholders before a big meeting, like voting on important decisions. It explains what's being voted on and gives important information so shareholders can make informed choices. It matters because it helps shareholders understand and participate in key company decisions.

quorum financial

"the Company held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”), at which a quorum was present"

A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Evommune (EVMN) stockholders vote on at the 2026 annual meeting?

Evommune stockholders voted on electing two directors and ratifying the independent auditor. They elected Luis Peña and Eugene Bauer, M.D., and approved BDO USA, P.C. as auditor for the fiscal year ending December 31, 2026, with strong support.

Were Evommune (EVMN) director nominees elected at the 2026 annual meeting?

Yes, both director nominees were elected. Luis Peña received 21,859,596 votes for and 1,949,148 withheld, while Eugene Bauer, M.D. received 23,637,920 for and 170,824 withheld, along with 885,750 broker non-votes for each nominee.

How did Evommune (EVMN) stockholders vote on the 2026 auditor ratification proposal?

Stockholders approved BDO USA, P.C. as Evommune’s independent registered public accounting firm for 2026. The vote totaled 24,664,299 for, 430 against, and 29,765 abstentions, with no broker non-votes reported on the auditor ratification proposal.

Who will serve on Evommune’s (EVMN) board after the 2026 annual meeting vote?

Following the 2026 annual meeting, Luis Peña and Eugene Bauer, M.D. were elected to Evommune’s board. They will serve until the 2029 annual meeting of stockholders, or until their successors are duly elected and qualified, or earlier death, resignation, or removal.

When was Evommune’s (EVMN) 2026 annual meeting of stockholders held?

Evommune held its 2026 Annual Meeting of Stockholders on June 2, 2026. A quorum was present, allowing stockholders to vote on electing two directors and on ratifying BDO USA, P.C. as the company’s independent registered public accounting firm for 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/02/2026 - 04:07 PM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 2, 2026

Evommune, Inc.

(Exact Name of Registrant as Specified in Its Charter)


Delaware	001-42938	85-0742575
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

1891 Page Mill Road Palo Alto, CA		94304
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (925) 247-4487

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

     Title of each class

     Trading
Symbol(s)

     Name of each exchange on which registered

     Common Stock, $0.0001 par value per share

     EVMN

     The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 2, 2026, Evommune, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”), at which a quorum was present. At the Annual Meeting, the stockholders of the Company voted on the following two proposals, each of which is described in more detail in the Company’s definitive proxy statement (the “Proxy Statement”) filed with the Securities and Exchange Commission on April 21, 2026:

Proposal 1 – Election of Directors

The following nominees were elected to the Company’s Board of Directors to hold office until the Company's 2029 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified, or until their earlier death, resignation or removal. The votes cast at the Annual Meeting were as follows:


Nominee	For	Withheld	Broker Non-Votes
Luis Peña	21,859,596	1,949,148	885,750
Eugene Bauer, M.D.	23,637,920	170,824	885,750

Proposal 2 – Ratification of Selection of Independent Registered Public Accounting Firm

The proposal to ratify the selection of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was approved based upon the following votes:


For	Against	Abstain	Broker Non-Votes
24,664,299	430	29,765	—

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	Evommune, Inc.

Date: June 2, 2026	By:	/s/ Luis Peña
		Luis Peña
		President and Chief Executive Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document